We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Citizen Petition Alleges Genentech, Biogen Idec Promoted Off-Label Use of Rituxan
Citizen Petition Alleges Genentech, Biogen Idec Promoted Off-Label Use of Rituxan
March 3, 2006
Genentech and Biogen Idec allegedly paid doctors to promote an off-label use of their non-Hodgkin’s lymphoma drug Rituxan as a treatment for rheumatoid arthritis (RA) and other conditions, according to a citizen petition filed Feb. 24 by a researcher at a Chicago law firm representing a former Genentech employee who has sued the company.